Can Your Body Stop Responding to Fabry Disease ERT?

When you receive enzyme replacement therapy (ERT) for Fabry disease, your body is being infused with a synthetic version of the enzyme your body is missing (alpha-galactosidase A). Because your body is not used to making this enzyme naturally—especially if you are a male with “classic” Fabry disease—your immune system may see the new, synthetic enzyme as a foreign invader. In response, your immune system can produce anti-drug antibodies (ADAs) to attack and neutralize it ^[1][2].

Developing these antibodies is very common and completely out of your control—it simply means your immune system is doing what it thinks is right. However, if your body starts producing ADAs, it is fighting the very treatment meant to help you. This can make the ERT less effective over time.

How Antibodies Affect Your Treatment

Not all antibodies cause immediate problems, but if your body produces neutralizing antibodies, they can bind to the synthetic enzyme and block it from entering your cells where it is needed to clear out the toxic buildup of fatty substances ^[3].

When the treatment is neutralized, you may experience:

• Reduced Treatment Efficacy: The ERT can no longer do its job effectively, which can lead to a return or worsening of physical Fabry symptoms, such as nerve pain in your hands and feet or gastrointestinal issues ^[3][4].
• Increased Disease Biomarkers: Blood tests may show rising levels of lyso-Gb3, a key marker that indicates the disease is becoming more active ^[5].
• Disease Progression: Over the long term, uncontrolled Fabry disease can lead to continued organ damage, such as declining kidney function or worsening heart problems ^[3][4]. In one study, patients with neutralizing antibodies had a significantly higher need for dialysis or kidney transplantation ^[5]. However, routine monitoring is designed to catch antibodies early so your doctor can change your treatment strategy long before these severe complications occur.

How Doctors Monitor for Antibodies

Because ADAs can significantly impact your long-term health, your care team will monitor your response to ERT over time ^[6].

Monitoring typically involves regular blood tests (often every 3 to 6 months), especially during your first few years of treatment ^[7]. Doctors don’t just look for the presence of antibodies; they also measure:

• Antibody Titers: The total amount of antibodies in your blood.
• Neutralizing Activity: How well those antibodies are actually blocking the enzyme from working ^[5].
• Lyso-Gb3 Levels: If this biomarker is rising, it often indicates the ERT is no longer working as effectively ^[5].

What Happens if You Develop Antibodies?

If tests show that your body has stopped responding to ERT due to antibodies, your doctor has several strategies to adjust your treatment and regain control of your condition:

• Dose Escalation: Sometimes, doctors increase the dose of the ERT. The goal is to flood the body with more enzyme than the antibodies can block (a process called “saturating” the antibodies), allowing some of the enzyme to slip past the immune system and do its job ^[3][6].
• Switching ERT Formulations: There are different formulations of ERT (such as agalsidase alfa, agalsidase beta, and pegunigalsidase alfa). If you develop antibodies to one, switching to a newer formulation might evade your immune system’s current defenses ^[8][1]. For example, pegunigalsidase alfa has a protective coating that helps hide it from the immune system.
• Chaperone Therapy: If your specific genetic mutation is considered “amenable,” you might be able to switch to an oral medication called a pharmacological chaperone (migalastat). Because this medication isn’t an infused enzyme, it does not trigger the same antibody response ^[9].
• Immune Tolerance: In some cases, doctors might use specialized immunosuppressive medications to stop your immune system from fighting the ERT ^[10]. This requires careful monitoring, as it can temporarily increase your risk for other infections.